Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sanofi-Aventis spins off Novexel

Executive Summary

Sanofi-Aventis has spun off a new anti-infectives company it will call Novexel, which has received €40mm ($53mm) in venture funding. The investors, which hold a 66% interest in the company, were led by Atlas Venture and included Sofinnova Partners, 3i, and Novo AS. Sanofi-Aventis retains a 22% stake.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Spin-Off

Related Companies

Advertisement
UsernamePublicRestriction

Register